Search research articles
Contact Us
Filters
Showing results (1341-1350 of 1,358) with videos related to
Page
of 136
Sort By:
Free Radical Biology & Medicine
|
February 22, 2005
Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?
M B Kadiiska, B C Gladen, D D Baird, et al.
Nature Cancer
|
May 7, 2025
A population-based analysis of the molecular landscape of glioma in adolescents and young adults reveals insights into gliomagenesis
Julie Bennett, Adrian B Levine, Liana Nobre, et al.
Anesthesia and Analgesia
|
May 22, 2018
Evaluating Patient-Centered Outcomes in Clinical Trials of Procedural Sedation, Part 2 Safety: Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research Recommendations
Denham S Ward, Mark R Williams, John W Berkenbosch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Lancet (London, England)
|
August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
C Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
The Lancet. Oncology
|
October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Nature Medicine
|
May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Farshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
The Lancet. Oncology
|
May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Martin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology
|
December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Martin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Page
of 136
Search research articles
Search
Showing results (1341-1350 of 1,358) with videos related to
Sort By:
Page
of 136
Free Radical Biology & Medicine
|
February 22, 2005
Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?
M B Kadiiska, B C Gladen, D D Baird, et al.
Nature Cancer
|
May 7, 2025
A population-based analysis of the molecular landscape of glioma in adolescents and young adults reveals insights into gliomagenesis
Julie Bennett, Adrian B Levine, Liana Nobre, et al.
Anesthesia and Analgesia
|
May 22, 2018
Evaluating Patient-Centered Outcomes in Clinical Trials of Procedural Sedation, Part 2 Safety: Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research Recommendations
Denham S Ward, Mark R Williams, John W Berkenbosch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Lancet (London, England)
|
August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
C Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
The Lancet. Oncology
|
October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Nature Medicine
|
May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Farshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
The Lancet. Oncology
|
May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Martin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology
|
December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Martin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Page
of 136